{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-08T13:19:19.622832+00:00","company":{"ticker":"PVCT","cik":315545,"company_name":"PROVECTUS BIOPHARMACEUTICALS, INC."},"pagination":{"limit":100,"returned":7,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"University of Miami","detail":"license","count":1,"first_seen":"2024-03-27T23:59:59+00:00","last_seen":"2024-03-27T23:59:59+00:00","evidence_fact_ids":[64833]}]},"facts":[{"fact_type":"governance_change","fact_key":"873e6e2bf78e5340e8aedc46031192cff877bcde","cik":315545,"ticker":"PVCT","company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","filed_at":"2026-02-02T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2026-01-30","item_codes_triggered":["5.03"],"summary_text":"Extended the automatic conversion date of Series D and Series D-1 Convertible Preferred Stock from June 20, 2026 to December 31, 2028"},"claim":"PROVECTUS BIOPHARMACEUTICALS, INC.: Extended the automatic conversion date of Series D and Series D-1 Convertible Preferred Stock from June 20, 2026 to December 31, 2028 (effective 2026-01-30).","evidence_excerpt":"On January 30, 2026, Provectus Biopharmaceuticals, Inc. (the “Company”) filed a Certificate of Amendment to the Certificate of Designation of Preferences, Rights, and Limitations of Series D Convertible Preferred Stock (the “Series D Amendment”) and a Certificate of Amendment to the Certificate of Designation of Preferences, Rights, and Limitations of Series D-1 Convertible Preferred Stock (the “Series D-1 Amendment,” and together with the Series D Amendment, the “Amendments”) with the Secretary of State of the State of Delaware.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-004730","anchor_url":"https://secwatch.observer/filing/0001493152-26-004730#claim-873e6e2bf78e5340e8aedc46031192cff877bcde","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/315545/000149315226004730/0001493152-26-004730-index.htm"},{"fact_type":"executive_change","fact_key":"9aa90322c9","cik":315545,"ticker":"PVCT","company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","filed_at":"2024-04-16T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-04-16","interim":false,"role":"President","role_category":"president","successor_name":null,"successor_named":false},"claim":"Dominic Rodrigues was appointed as President at PROVECTUS BIOPHARMACEUTICALS, INC..","evidence_excerpt":"appointed Dominic Rodrigues as the Company’s President effective April 16, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-014848","anchor_url":"https://secwatch.observer/filing/0001493152-24-014848#claim-9aa90322c9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/315545/000149315224014848/0001493152-24-014848-index.htm"},{"fact_type":"executive_change","fact_key":"9d03046c81","cik":315545,"ticker":"PVCT","company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","filed_at":"2024-04-16T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-04-16","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Ed Pershing was appointed as Chief Executive Officer at PROVECTUS BIOPHARMACEUTICALS, INC..","evidence_excerpt":"appointed Ed Pershing as the Company’s Chief Executive Officer effective April 16, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-014848","anchor_url":"https://secwatch.observer/filing/0001493152-24-014848#claim-9d03046c81","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/315545/000149315224014848/0001493152-24-014848-index.htm"},{"fact_type":"material_agreement","fact_key":"a7710c04f563731c761aa3232156b13ff1264e03","cik":315545,"ticker":"PVCT","company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","filed_at":"2024-03-27T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Exclusive License Agreement","agreement_type":"license","counterparty":"University of Miami","effective_date":"2024-03-21","item_codes_triggered":["1.01"],"value_text":null},"claim":"PROVECTUS BIOPHARMACEUTICALS, INC. entered into Exclusive License Agreement with University of Miami (effective 2024-03-21).","evidence_excerpt":"On March 21, 2024, Provectus Biopharmaceuticals, Inc. (the “Company”) entered into an Exclusive License Agreement (the “License Agreement”) with the University of Miami (the “University”) for the license and development of the University’s intellectual property related to photodynamic antimicrobial therapy in ophthalmology.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-011443","anchor_url":"https://secwatch.observer/filing/0001493152-24-011443#claim-a7710c04f563731c761aa3232156b13ff1264e03","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/315545/000149315224011443/0001493152-24-011443-index.htm"},{"fact_type":"executive_change","fact_key":"08841473e0","cik":315545,"ticker":"PVCT","company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","filed_at":"2024-03-26T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-03-25","interim":false,"role":"Chief Operations Consultant","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Dominic Rodrigues was appointed as Chief Operations Consultant at PROVECTUS BIOPHARMACEUTICALS, INC..","evidence_excerpt":"the Board retained Dominic Rodrigues as the Company’s chief operations consultant.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-011327","anchor_url":"https://secwatch.observer/filing/0001493152-24-011327#claim-08841473e0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/315545/000149315224011327/0001493152-24-011327-index.htm"},{"fact_type":"executive_change","fact_key":"b2400c61ba","cik":315545,"ticker":"PVCT","company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","filed_at":"2024-03-26T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"for_cause_or_dispute","effective_date":"2024-03-25","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Bruce Horowitz resigned as Director at PROVECTUS BIOPHARMACEUTICALS, INC..","evidence_excerpt":"On March 25, 2024, Bruce Horowitz resigned from the Board of Directors (the “Board”) of Provectus Biopharmaceuticals, Inc. (the “Company”) and as the Company’s Chief Operating Officer.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-011327","anchor_url":"https://secwatch.observer/filing/0001493152-24-011327#claim-b2400c61ba","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/315545/000149315224011327/0001493152-24-011327-index.htm"},{"fact_type":"executive_change","fact_key":"65456737d7","cik":315545,"ticker":"PVCT","company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","filed_at":"2024-03-26T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"for_cause_or_dispute","effective_date":"2024-03-25","interim":false,"role":"Chief Operating Officer","role_category":"coo","successor_name":null,"successor_named":false},"claim":"Bruce Horowitz resigned as Chief Operating Officer at PROVECTUS BIOPHARMACEUTICALS, INC..","evidence_excerpt":"On March 25, 2024, Bruce Horowitz resigned from the Board of Directors (the “Board”) of Provectus Biopharmaceuticals, Inc. (the “Company”) and as the Company’s Chief Operating Officer.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-011327","anchor_url":"https://secwatch.observer/filing/0001493152-24-011327#claim-65456737d7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/315545/000149315224011327/0001493152-24-011327-index.htm"}]}